IMAGE-HF: Project IIa Canadian CArdiomyopathy Registry for Device Therapy

IMAGE-HF: Project IIa - Canadian CArdiomyopathy Registry for Device Therapy (CanCARD-MR)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04908306

Acronym

CanCARD-MR

Enrollment

502

Registered

2021-06-01

Start date

2011-10-11

Completion date

2024-07-12

Last updated

2026-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Delayed enhanced MRI in patients (of either ischemic or non-ischemic cause) being referred for primary prevention ICD

Detailed description

Device therapy using defibrillators and cardiac resynchronization therapy (CRT) is an important advance in the care of patients with acquired heart disease and heart failure. In specific groups these devices appear to significantly reduce the risk of sudden cardiac death and progression of heart failure. However, our ability to identify ideal candidates, and those who are most likely to respond and benefit from this therapy, is poor. Preliminary studies using specialized Magnetic Resonance Imaging (MRI) appears to be one of the more valuable ways of predicting response to device therapy and holds substantial promise for patients with cardiomyopathy. Large, prospective registries are necessary to explore its real-world utility for risk prediction across a broad spectrum of patients. Can-CARD MR is a national, multi-centre registry designed to address this particular need.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* .Any patient accepted for primary prevention ICD (+/-) CRT)

Exclusion criteria

* Known contra-indications to MRI. * Recent myocardial infarction or revascularization procedure within the past 3 months. * GFR (glomerular filtration rate) ≤ 30 ml. / min/ m2.

Design outcomes

Primary

Measure	Time frame	Description
Occurrence of a)appropriate ICD therapy (shock or anti-tachycardia pacing (ATP)) or sudden cardiac death	1 year	Occurrence of a)appropriate ICD therapy (shock or anti-tachycardia pacing (ATP)) or sudden cardiac death

Contacts

PRINCIPAL_INVESTIGATORDavid Birnie

Ottawa Heart Institute Research Corporation

Outcome results